Cargando…
IL-21 in cancer immunotherapy: At the right place at the right time
Interleukin-21 (IL-21) has been described as a potent stimulator of antitumor T-cell immunity, but also of autoimmune reactions and oncogenesis. Antigen presenting cells genetically modified to release IL-21 allow for the expansion of tumor-specific T cells exhibiting favorable effector and growth c...
Autores principales: | Santegoets, Saskia JAM, Turksma, Annelies W., Powell Jr., Daniel J, Hooijberg, Erik, de Gruijl, Tanja D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716748/ https://www.ncbi.nlm.nih.gov/pubmed/23894713 http://dx.doi.org/10.4161/onci.24522 |
Ejemplares similares
-
Activation of antigen-exposed iMC-DCs at the “right place” and “right time” promotes potent anti-tumor immunity
por: Spencer, David M.
Publicado: (2012) -
IL-21 promotes the expansion of CD27(+)CD28(+) tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells
por: Santegoets, Saskia JAM, et al.
Publicado: (2013) -
Targeting the right regulatory T-cell population for tumor immunotherapy
por: Weiss, Vivian L., et al.
Publicado: (2012) -
Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients
por: Turksma, Annelies W, et al.
Publicado: (2013) -
Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?
por: Swarbrick, Alexander, et al.
Publicado: (2013)